U.K. Epilepsy and Pregnancy Group

Russell, Aline; Craig, John; Morrison, Patrick J.; Irwin, B.; Waddell, R.; Parsons, L.; Robertson, Ian; Guthrie, Eleanor; Morrow, Jim

doi:10.1111/j.0013-9580.2004.451104.x

Cited by 29 publications

(10 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[19][20][21][22][23][24] The International Lamotrigine Pregnancy Register was the first to report on a substantial number of pregnancies exposed to one of the newer AEDs. 25 Initial results based on 334 first trimester lamotrigine outcomes showed an MCM rate for 168 monotherapy outcomes of 1.8% (95% CI, 0.5% to 5.5%) and 6.0% for 166 polytherapy exposures.…”

Section: Discussionmentioning

confidence: 99%

Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register

Morrow

Russell²,

Guthrie³

et al. 2006

Journal of Neurology, Neurosurgery & Psychiatry

782

585

View full text Add to dashboard Cite

Objective: To assess the relative risk of major congenital malformation (MCM) from in utero exposure to antiepileptic drug (AEDs). Methods: Prospective data collected by the UK Epilepsy and Pregnancy Register were analysed. The presence of MCMs recorded within the first three months of life was the main outcome measure. Results: Full outcome data were collected on 3607 cases. The overall MCM rate for all AED exposed cases was 4.2% (95% confidence interval (CI), 3.6% to 5.0%). The MCM rate was higher for polytherapy (6.0%) (n = 770) than for monotherapy (3.7%) (n = 2598) (crude odds ratio (OR) = 1.63 (p = 0.010), adjusted OR = 1.83 (p = 0.002)). The MCM rate for women with epilepsy who had not taken AEDs during pregnancy (n = 239) was 3.5% (1.8% to 6.8%). The MCM rate was greater for pregnancies exposed only to valproate (6.2% (95% CI, 4.6% to 8.2%) than only to carbamazepine (2.2% (1.4% to 3.4%) (OR = 2.78 (p,0.001); adjusted OR = 2.97 (p,0.001)). There were fewer MCMs for pregnancies exposed only to lamotrigine than only to valproate. A positive dose response for MCMs was found for lamotrigine (p = 0.006). Polytherapy combinations containing valproate carried a higher risk of MCM than combinations not containing valproate (OR = 2.49 (1.31 to 4.70)). Conclusions: Only 4.2% of live births to women with epilepsy had an MCM. The MCM rate for polytherapy exposure was greater than for monotherapy exposure. Polytherapy regimens containing valproate had significantly more MCMs than those not containing valproate. For monotherapy exposures, carbamazepine was associated with the lowest risk of MCM.

show abstract

Section: Discussionmentioning

confidence: 99%

Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register

Morrow

Russell²,

Guthrie³

et al. 2006

Journal of Neurology, Neurosurgery & Psychiatry

782

585

View full text Add to dashboard Cite

show abstract

“…WWE were recruited through the UKEPR, a prospective register of WWE designed for the collection of data pertaining to pregnancy and outcome. 11 Eligibility criteria for enrollment onto the current study included use of monotherapy LEV throughout pregnancy, with a live birth between December 2003 and September 2007, or monotherapy VPA throughout pregnancy with a live birth between September 2005 and September 2007. Further criteria included maternal IQ .70 and children aged between 36 and 54 months at time of assessment.…”

mentioning

confidence: 99%

In utero exposure to levetiracetam vs valproate

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The North American Anti epileptic drug pregnancy registry, the United Kingdom Epilepsy and Pregnancy group and Australian pregnancy registry and Kerala pregnancy registry are also independent academic registries [48][49][50]. The Australian and Kerala registries have recently merged into EURAP.…”

Section: Teratogenic Effects Of Epilepsy and Aedsmentioning

confidence: 99%